Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Theratechnologies will need to address FDA's concerns about whether a reduction of patients' visceral abdominal fat produced by the HIV lipodystrophy product has clinical meaning and is worth the risks.
Advertisement

Related Content

Egrifta Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes
Egrifta Post-marketing Study On Diabetic Retinopathy Will Include CV Outcomes
Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies
Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies
Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation
Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation
Egrifta, With Help From Patient Testimonies, Gets Advisory Committee Recommendation
When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
GSK Brings HCV Assets Into Its Infectious Diseases R&D Center

Topics

Advertisement
UsernamePublicRestriction

Register

PS070678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel